Motley Fool blaming plunge on earnings "falling short of expectations" but there seems to be more to the back-story: however if only the IR head was reprimanded and new CEO cleared, with approval of NeuVax and rave reviews and results in ltd. trials, this co. should be vindicated...eventually...lousy investment meanwhile unfortunately, some of us have too many shares already.
Many bargain-hunters ARE snapping up shares @these cheap prices, unfortunately selling on any rise approaching $2.00, gotta break that.
It's on many short lists of biotechs that can easily triple within a year or so...c'mon Galena, time to explode w/ some big news now that SEC isn't breathing down your neck anymore.
Schwarz seems to be bending over backwards to do NO PR meanwhile.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.